Abstract
Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) each account for approximately 5% of liver transplants per year performed in the United States and Europe. Even though outcomes are excellent, with reported 5-year patient and graft survival exceeding 90% and 80%, 80% and 75%, 72% and 65% for PBC, PSC, and AIH, respectively, the issue of recurrent autoimmune liver disease after orthotopic liver transplantation is increasingly recognized as a cause of graft dysfunction, death, and need for retransplantation. This article reviews diagnostic criteria, epidemiology, risk factors, and outcomes of recurrent PBC, PSC, and AIH after liver transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 859-878 |
| Number of pages | 20 |
| Journal | Clinics in liver disease |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 1 2011 |
Keywords
- Autoimmune hepatitis
- Liver transplantation
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Recurrence
ASJC Scopus subject areas
- Hepatology
Fingerprint Dive into the research topics of 'Recurrent and De Novo Autoimmune Liver Diseases'. Together they form a unique fingerprint.
Cite this
Mendes, F., Couto, C. A., & Levy, C. (2011). Recurrent and De Novo Autoimmune Liver Diseases. Clinics in liver disease, 15(4), 859-878. https://doi.org/10.1016/j.cld.2011.08.008